Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. September 2014 07:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202

NEW YORK, Sept. 23, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the Company's novel, next...
15. September 2014 07:00 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia

Overall Response Rate (ORR) to be the Primary Endpoint to Support Accelerated Approval with Progression-Free Survival (PFS) to Support Full Approval Safety and Efficacy Data from Over 30 CLL...
08. September 2014 16:27 ET | Quelle: TG Therapeutics, Inc.

UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference

NEW YORK, Sept. 8, 2014 (GLOBE NEWSWIRE) -- In a release issued earlier today by TG Therapeutics, Inc. (Nasdaq:TGTX), please note the company's scheduled presentation time has changed to 1:15 PM ET,...
08. September 2014 09:25 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference

NEW YORK, Sept. 8, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that Michael Weiss, the Company's Interim Chief...
15. August 2014 07:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics Announces Novel "Chemo-free" Triple Therapy Combination Clinical Study for Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies

NEW YORK, Aug. 15, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced the commencement of a novel triple therapy clinical study that combines the Company's two...
21. Juli 2014 16:05 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics' Novel Combination of TG-1101 (Ublituximab) and TGR-1202 Demonstrates Compelling Early Activity and Safety Profile in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) and Aggressive Lymphomas

100% of CLL/SLL patients had significant nodal reduction with either a normalization of or ≥80% reduction in Blood Lymphocyte Count 4 of 5 CLL/SLL patients achieved a partial response...
21. Juli 2014 16:05 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Business Update

Investor Conference Call to be held July 22, 2014 at 8:30am EDT to discuss Second Quarter Financial Results and Preliminary Clinical Data Presented at The Pan Pacific Lymphoma Conference announced...
24. Juni 2014 08:08 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics Completes Global Licensing Agreement With Ligand Pharmaceuticals for the Development of Inhibitors of IRAK4

NEW YORK, June 24, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), announced today an agreement with Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) to license exclusive global rights...
23. Juni 2014 08:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. to Present at the 2014 JMP Securities Healthcare Conference

NEW YORK, June 23, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that Michael Weiss, the Company's Interim Chief...
16. Juni 2014 16:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. to Present at the 2014 Wells Fargo Healthcare Conference

NEW YORK, June 16, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that Michael Weiss, the Company's Interim Chief...

Vorherige Seite